- Home
- BOWL vs VRDN Comparison
BOWL vs VRDN Comparison
Compare BOWL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWL
- VRDN
- Stock Information
- Founded
- BOWL 1900
- VRDN 2006
- Country
- BOWL United States
- VRDN United States
- Employees
- BOWL N/A
- VRDN N/A
- Industry
- BOWL Services-Misc. Amusement & Recreation
- VRDN Medical Specialities
- Sector
- BOWL Consumer Discretionary
- VRDN Health Care
- Exchange
- BOWL Nasdaq
- VRDN Nasdaq
- Market Cap
- BOWL 1.6B
- VRDN 1.5B
- IPO Year
- BOWL N/A
- VRDN N/A
- Fundamental
- Price
- BOWL $11.45
- VRDN $20.14
- Analyst Decision
- BOWL Strong Buy
- VRDN Strong Buy
- Analyst Count
- BOWL 9
- VRDN 10
- Target Price
- BOWL $15.88
- VRDN $37.25
- AVG Volume (30 Days)
- BOWL 722.4K
- VRDN 1.1M
- Earning Date
- BOWL 11-04-2024
- VRDN 11-12-2024
- Dividend Yield
- BOWL 1.92%
- VRDN N/A
- EPS Growth
- BOWL N/A
- VRDN N/A
- EPS
- BOWL N/A
- VRDN N/A
- Revenue
- BOWL $1,187,404,000.00
- VRDN $302,000.00
- Revenue This Year
- BOWL $10.34
- VRDN N/A
- Revenue Next Year
- BOWL $6.91
- VRDN N/A
- P/E Ratio
- BOWL N/A
- VRDN N/A
- Revenue Growth
- BOWL 12.45
- VRDN N/A
- 52 Week Low
- BOWL $9.71
- VRDN $11.40
- 52 Week High
- BOWL $15.47
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- BOWL 49.35
- VRDN 36.38
- Support Level
- BOWL $11.06
- VRDN $22.40
- Resistance Level
- BOWL $12.23
- VRDN $27.20
- Average True Range (ATR)
- BOWL 0.63
- VRDN 1.36
- MACD
- BOWL 0.03
- VRDN -0.41
- Stochastic Oscillator
- BOWL 51.03
- VRDN 6.37
About BOWL Bowlero Corp.
Bowlero Corp is a operator of bowling entertainment centers. It operate traditional bowling centers and more upscale entertainment concepts with lounge seating, arcades, enhanced food and beverage offerings, and more robust customer service for individuals and group events, as well as hosting and overseeing professional and non-professional bowling tournaments and related broadcasting.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.